Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Commentary|Articles|July 15, 2026
Kerry Rogers, MD, Talks BTK Inhibitor Sequencing, Cost, Access in CLL
Author(s)Maggie L. Shaw, Kerry Rogers, MD
Fact checked by: Laura Joszt, MA
Kerry Rogers, MD, at The James, unpacks what these questions mean for patient counseling and clinical trial equity in chronic lymphocytic leukemia (CLL).
Advertisement
Advertisement
The evolving Bruton tyrosine kinase (BTK) inhibitor landscape for
Related to this article
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Patient factors and access barriers are reshaping treatment sequencing and individualized care for relapsed multiple myeloma, Amandeep Godara, MBBS, said.
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
Working-age adults with private insurance are paying off medical debt, often draining savings, delaying care, or cutting back on necessities as a result.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg
Advertisement
Advertisement